PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity

Journal of Lipid Research

Volumn 45, Issue 10, 2004, Pages 1852-1858

  Yan, Daoguang ^a   Navab, Mohamad ^b   Bruce, Can ^a   Fogelman, Alan M ^b   Jiang, Xian Cheng ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

High density lipoprotein; Low density lipoprotein; Phospholipid; Phospholipid transfer protein

Indexed keywords

APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID TRANSFER PROTEIN; MEMBRANE PROTEIN; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CHEMOTAXIS; CONTROLLED STUDY; EXPOSURE; HUMAN; HUMAN CELL; INFLAMMATION; KNOCKOUT MOUSE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MONOCYTE; MOUSE; NONHUMAN; PHOSPHOLIPID TRANSFER PROTEIN DEFICIENCY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TRANSGENIC MOUSE; ANIMAL; BLOOD; COCULTURE; CYTOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; APOLIPOPROTEINS B; CHEMOTAXIS, LEUKOCYTE; CHOLESTEROL ESTERS; COCULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MONOCYTES; PHOSPHATIDYLCHOLINES; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHOLIPIDS;

EID: 16644402295     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M400053-JLR200     Document Type: Article

References (26)

1. Tall, A. R. 1986. Plasma lipid transfer proteins. J. Lipid Res. 27: 359-365.
2. Tall, A. R., S. Krumholz, T. Olivercona, and R. J. Deckelbaum. 1985. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid Res. 26: 842-852.
3. Jauhianinen, M., J. Metso, R. Pohlman, S. Blomquist, A. van Tol, and C. Ehnholm. 1993. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem. 268: 4032-4036.
4. Tu, A. Y., H. I. Nishida, and T. Nishida. 1993. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J. Biol. Chem. 268: 23098-23105.
5. Tollefson, J. H., S. Ravnik, and J. J. Albers. 1988. Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J. Lipid Res. 29: 1593-1601.
6. Jiang, X. C., C. Bruce, J. Mar, M. Lin, Y. Ji, O. L. Francone, and A. R. Tall. 1999. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103: 907-914.
7. Jiang, X. C., S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao, and A. R. Tall. 2001. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7: 847-852.
8. Jiang, X. C., A. R. Tall, S. Qin, M. Lin, M. Shneider, F. Lalanne, V. Deckert, C. Desrumaux, A. Athias, J. Witztum, and L. Lagrost. 2002. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J. Biol. Chem. 277: 39561-39566.
9. van Haperen, R., A. van Tol, P. Vermeulen, M. Jauhiainen, T. van Gent, P. van den Berg, S. Ehnholm, F. Grosveld, A. van der Kamp, and R. de Crom. 2000. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 20: 1082-1088.
10. van Haperen, R., A. van Tol, T. van Gent, L. Scheck, P. Visser, A. van Der Kamp, F. Grosveld, and R. De Crom. 2002. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277: 48938-48943.
11. Lie, J., R. De Crom, T. Van Gent, R. Van Haperen, L. Scheek, I. Lankhuizen, and A. van Tol. 2002. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J. Lipid Res. 43: 1875-1880.
12. Yang, X. P., D. Van, C. Qiao, R. J. Liu, J. G. Chen, J. Li, M. Schneider, L. Lagrost, X. Xiao, and X. C. Jiang. 2003. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler. Thromb. Vasc. Biol. 23: 1601-1607.
13. Qin, S., K. Kawano, C. Bruce, M. Lin, C. Bisgaier, A. R. Tall, and X. C. Jiang. 2000. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J. Lipid Res. 41: 269-276.
14. 131I-labeled plasma proteins. Phys. Med. Biol. 2: 36-53.
15. Brinton, E. A., S. Eisenberg, and J. L. Breslow. 1994. Human HDL cholesterol levels are determined by apoAI fractional rate, which correlates inversely with estimates of HDL particle size. Arterioscler. Thromb. 14: 707-720.
16. Navab, M., S. Y. Hama, S. T. Reddy, C. J. Ng, B. J. Van Lenten, H. Laks, A. M. Fogelman, and S. T. Ready. 2002. Oxidized lipids as mediators of coronary heart disease. Curr. Opin. Lipidol. 13: 363-372.
17. Navab, M., S. Y. Hama, C. J. Cooke, G. M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K. F. Faull, S. T. Reddy, N. E. Miller, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41: 1481-1494.
18. Navab, M., S. Y. Hama, G. P. Hough, G. Subbanagounder, S. T. Reddy, and A. M. Fogelman. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42: 1308-1317.
19. Song, H., K. Saito, S. Fujigaki, A. Noma, H. Ishiguro, T. Nagatsu, and M. Seishima. 1998. IL-1 beta and TNF-alpha suppress apolipoprotein (apo) E secretion and apo A-I expression in HepG2 cells. Cytokine. 10: 275-280.
20. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
21. Navab, M., S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495-1508.
22. Graham, A., D. G. Hassall, S. Rafique, and J. S. Owen. 1997. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135: 193-204.
23. Schaefer, E. J., C. B. Blum, R. I. Levy, L. L. Jenkins, P. Alaupovic, D. M. Foster, and H. B. Brewer, Jr. 1978. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N. Engl. J. Med. 299: 905-910.
24. Aiello, R. J., D. Brees, and O. L. Francone. 2003. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler. Thromb. Vasc. Biol. 23: 972-980.
25. Genest, J. J., Jr., S. S. Martin-Munley, J. R. McNamara, J. M. Ordovas, J. Jenner, R. H. Myers, S. R. Silberman, P. W. Wilson, D. N. Salem, and E. J. Schaefer. 1992. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85: 2025-2033.
26. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, and A. M. Fogelman. 2003. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756.